Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Issues in antithrombin therapy for UA/NSTEMI
Autore:
Alpert, JS; Budaj, AJ; Gurfinkel, EP; Henry, TD;
Indirizzi:
Univ Arizona, Coll Med, Tucson, AZ 85721 USA Univ Arizona Tucson AZ USA 85721 Arizona, Coll Med, Tucson, AZ 85721 USA Postgrad Med Sch, Warsaw, Poland Postgrad Med Sch Warsaw PolandPostgrad Med Sch, Warsaw, Poland Favoloro Fdn, Buenos Aires, DF, Argentina Favoloro Fdn Buenos Aires DF Argentina Fdn, Buenos Aires, DF, Argentina Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA Hennepin Cty Med Ctr Minneapolis MN USA 55415 , Minneapolis, MN 55415 USA
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: J, volume: 3, anno: 2001,
pagine: J15 - J23
SICI:
1520-765X(200108)3:J<J15:IIATFU>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE CORONARY SYNDROMES; MOLECULAR-WEIGHT HEPARIN; ST-SEGMENT ELEVATION; WAVE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; UNFRACTIONATED HEPARIN; ACC/AHA GUIDELINES; RANDOMIZED TRIAL; ARTERY DISEASE; TASK-FORCE;
Keywords:
unstable angina; antithrombin; heparin; low-molecular-weight heparin; guidelines;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Alpert, JS Univ Arizona, Coll Med, Tucson, AZ 85721 USA Univ Arizona Tucson AZ USA 85721 oll Med, Tucson, AZ 85721 USA
Citazione:
J.S. Alpert et al., "Issues in antithrombin therapy for UA/NSTEMI", EUR H J SUP, 3(J), 2001, pp. J15-J23

Abstract

In September 2000, participants at the 4th Annual Experts' Meeting of the International Cardiology Forum convened to discuss guidelines for the management of unstable angina/non-ST-elevation MI, recently published by North American and European task forces. Discussion of new recommendations for antithrombin therapy focused on the role of low-molecular-weight heparin (LMWH). Although most participants found the new guidelines largely consistent with existing data, and sufficiently adaptable to most clinical settings, there was concern that neither task force specified LMWH as the antithrombin of choice for the medical management of these patients. The new guidelines continue to endorse the use of unfractionated heparin, particularly for high-risk patients, despite the evidence for the efficacy of LMWH in this setting. This is largely a consequence of the dominant role assigned to the GP IIb/IIIa inhibitors and to an early interventional strategy. It was generally agreed that more data on the use of LMWH in combination with GP IIb/IIIaantagonists would be helpful. as well as more information to guide the transition from medical management to the cath lab. The optimal duration of antithrombin therapy was also the subject of discussion, particularly for patients unable to undergo immediate revascularization. (C) 2001 The European Society of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 21:49:05